Intensive therapy should achieve glycemic control while avoiding severe and nocturnal hypoglycemia as much as possible. Physiologic, behavioral, and pharmacologic factors contribute to nocturnal ...

These second-generation basal insulin analogs, Gla-300 and IDeg-100, also had similar safety profiles, investigators found. A new study of second-generation basal insulin analogs shows insulin ...

Key market opportunities include growing demand for rapid-acting insulin analogues, integration with digital monitoring tools, and expanding geriatric diabetic population. Personalized diabetes ...

Two long-acting insulin analogs have been developed for use as "basal" components of insulin treatment regimens: glargine and detemir. (Insulin glargine has US Food and Drug Administration [FDA] ...

Use of analog vs human insulin in patients receiving hemodialysis is associated with a lower risk for major adverse cardiovascular events, hospitalization, and death. Treatment with analog rather than ...

GZR4 demonstrated statistically significant HbA1c reductions compared with insulin glargine U100 and insulin degludec, with no reported severe hypoglycemic events. Topline results were announced from ...

A century ago, type 1 diabetes was a death sentence. Children diagnosed rarely survived more than a year or two, wasting away as their bodies starved despite food. Then, in 1921, in a modest lab in ...

ORLANDO -- Most adults with type 1 diabetes switching from an insulin pump or multiple daily injections to inhaled insulin (Afrezza) needed to increase their dose of the inhaled product to achieve ...

Insulin remains one of the most important treatments for people living with diabetes. Whether someone has Type 1 diabetes or advanced Type 2 diabetes, insulin therapy helps control blood sugar levels, ...

Novo Nordisk added the final piece to the puzzle the Danish drugmaker wanted to complete before submitting its once-weekly insulin icodec to regulators next year. Icodec already notched notable wins ...